NCT02201550已完成不适用
Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Change in number of specific immune cells in blood detected by flow cytometry
研究概览
简要总结
The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes.
The hypotheses are:
- Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood
- Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood
- Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes
- •BMI > 27 kg/m2
- •Planed start of treatment with liraglutide
- •Age > 18 years
排除标准
- •Infection or active inflammatory disorder
- •Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids)
- •Alcohol consumption > 14 beverages/week
- •Former bariatric surgery
结局指标
主要结局
Change in number of specific immune cells in blood detected by flow cytometry
时间窗: Before and 12 weeks after initiation of liraglutide treatment
次要结局
未报告次要终点
研究者
Carsten Dirksen
MD, PhD
Hvidovre University Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist TreatmentOverweight and ObesityNCT06069622Brigham and Women's Hospital30
已完成
不适用
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in DiabetesObesityType 2 DiabetesNCT01363609Amsterdam UMC, location VUmc50
Enrolling By Invitation
不适用
Adaptive Immune Response in Visceral and Subcutaneous Fat: Role in Human Insulin ResistanceInsulin SensitivityInflammationObesityInsulin ResistanceNCT04708535Stanford University50
已完成
1 期
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus, Type 2NCT01449019Ludwig-Maximilians - University of Munich24
已完成
1 期
Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in HumansAppetite and General Nutritional DisordersNCT01900340University Hospital, Basel, Switzerland12